Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1120212 versus docetaxel in second-line KRAS/NRAS/BRAF/MEK1-mutated metastatic NSCLC (Phase II)
2011-000634-11Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trametinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Progression-Free Survival. Started Jun 2011; status: completed.
02
Drugs
trametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-000634-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000634-11.